LYRA THERAPEUTICS INC (LYRA) Stock Price & Overview
NASDAQ:LYRA • US55234L2043
The current stock price of LYRA is 1.34 USD. Today LYRA is up by 2.29%. In the past month the price decreased by -2.19%. In the past year, price decreased by -84.42%.
LYRA Key Statistics
- Market Cap
- 2.372M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -22.89
- Dividend Yield
- N/A
LYRA Stock Performance
LYRA Stock Chart
LYRA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to LYRA. When comparing the yearly performance of all stocks, LYRA is a bad performer in the overall market: 98.35% of all stocks are doing better.
LYRA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LYRA. Both the profitability and financial health of LYRA have multiple concerns.
LYRA Earnings
On March 11, 2026 LYRA reported an EPS of -3.38 and a revenue of 25.00K. The company beat EPS expectations (36.94% surprise) and missed revenue expectations (-87.43% surprise).
LYRA Forecast & Estimates
6 analysts have analysed LYRA and the average price target is 16.32 USD. This implies a price increase of 1117.91% is expected in the next year compared to the current price of 1.34.
For the next year, analysts expect an EPS growth of 63.39% and a revenue growth -51.56% for LYRA
LYRA Groups
Sector & Classification
LYRA Financial Highlights
Over the last trailing twelve months LYRA reported a non-GAAP Earnings per Share(EPS) of -22.89. The EPS increased by 69.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -75.38% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
LYRA Ownership
LYRA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 27.96 | 943.209B | ||
| JNJ | JOHNSON & JOHNSON | 20.78 | 585.582B | ||
| MRK | MERCK & CO. INC. | 22.4 | 287.316B | ||
| PFE | PFIZER INC | 9 | 155.235B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.31 | 122.147B | ||
| ZTS | ZOETIS INC | 16.31 | 50.567B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.88 | 26.934B | ||
| VTRS | VIATRIS INC | 5.5 | 16.085B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.56 | 11.659B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.158B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.518B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.968B | ||
| LGND | LIGAND PHARMACEUTICALS | 24.91 | 4.412B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LYRA
Company Profile
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. The company is headquartered in Watertown, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2020-05-01. The firm is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The firm is developing therapies for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210, the Company’s lead product, is a bioabsorbable nasal implant designed to be administered in a simple, in-office procedure and is intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration. LYR-210, being evaluated in the ENLIGHTEN Phase III clinical program, is intended for patients with and without nasal polyps. The drug embedded within LYR-210 is mometasone furoate (MF).
Company Info
IPO: 2020-05-01
LYRA THERAPEUTICS INC
480 Arsenal Way
Watertown MASSACHUSETTS 02472 US
CEO: Maria Palasis
Employees: 30
Phone: 16173734600
LYRA THERAPEUTICS INC / LYRA FAQ
What does LYRA do?
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. The company is headquartered in Watertown, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2020-05-01. The firm is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The firm is developing therapies for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210, the Company’s lead product, is a bioabsorbable nasal implant designed to be administered in a simple, in-office procedure and is intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration. LYR-210, being evaluated in the ENLIGHTEN Phase III clinical program, is intended for patients with and without nasal polyps. The drug embedded within LYR-210 is mometasone furoate (MF).
Can you provide the latest stock price for LYRA THERAPEUTICS INC?
The current stock price of LYRA is 1.34 USD. The price increased by 2.29% in the last trading session.
Does LYRA THERAPEUTICS INC pay dividends?
LYRA does not pay a dividend.
What is the ChartMill technical and fundamental rating of LYRA stock?
LYRA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting LYRA stock to perform?
6 analysts have analysed LYRA and the average price target is 16.32 USD. This implies a price increase of 1117.91% is expected in the next year compared to the current price of 1.34.
What is the Price/Earnings (PE) ratio of LYRA THERAPEUTICS INC (LYRA)?
LYRA THERAPEUTICS INC (LYRA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-22.89).
Is LYRA THERAPEUTICS INC (LYRA) expected to grow?
The Revenue of LYRA THERAPEUTICS INC (LYRA) is expected to decline by -51.56% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.